GastroMARK® belongs to the negative oral contrast agents (same as Lumirem®, another brand name for ferumoxsil). GastroMARK® is used to distinguish the loops of the bowel from other abdominal structures and physiology. When GastroMARK® is ingested, it flows through and darkens the stomach and the small intestine in 30 to 45 minutes. By more clearly identifying the intestinal loops, GastroMARK® improves visualization of adjacent abdominal tissues such as the pancreas.

The company changed its name from Advanced Magnetics, Inc. to AMAG Pharmaceuticals, Inc. in July 2007.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, developed and manufactured organ-specific diagnostic contrast agents that provide clearer images during magnetic resonance imaging (MRI) tests used to detect tumors and other abnormalities.
The company had two MRI related products on the market: Feridex I.V. (for the diagnosis of liver lesions) and GastroMARK (used for bowel and abdominal MR imaging). In November 2008, AMAG Pharmaceuticals, Inc. decided to discontinue the manufacturing of Feridex. The development of Combidex as a contrast agent for lymph disease has also been stopped.
The Company has now two commercial products: Feraheme® and GastroMARK®. Feraheme® is the trade name of Ferumoxytol (formerly Code 7228) and is indicated for the treatment of iron deficiency anemia. Feraheme® is also being developed as a diagnostic agent for vascular-enhanced magnetic resonance imaging (MRI) to assess peripheral arterial disease.

MRI Contrast Agents:

Lumirem® belongs to the negative oral contrast agents (same as GastroMARK®, another brand name for ferumoxsil). Lumirem® is used to distinguish the loops of the bowel from other abdominal structures and physiology. When Lumirem® is ingested, it flows through and darkens the stomach and the small intestine in 30 to 45 minutes. By more clearly identifying the intestinal loops, Lumirem® improves visualization of adjacent abdominal tissues such as the pancreas.
Additionally, in Europe Lumirem® is approved for rectal administration to delineate the lower intestinal system.

Mallinckrodt, a Tyco Healthcare company makes and distributes products for respiratory care; bulk and dosage pharmaceuticals, primarily for pain relief and addiction therapy; and imaging agents for magnetic resonance, ultrasound, X-ray, and nuclear medicine applications. With worldwide manufacturing and distribution facilities, as well as worldwide sales offices, Mallinckrodt sells its products worldwide.
GastroMARK® is marketed in the United States by Mallinckrodt, Inc.

In June 2007 Tyco International Ltd. completed the separation of its healthcare business, which is named Covidien. Mallinckrodt, Inc. is now part of Covidien Ltd.

MRI Contrast Agents:

(GastroMARK®, Lumirem®) A superparamagnetic MRI contrast agent for the gastrointestinal tract.

See also Oral Contrast Agents.